Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Shingles Health Center

Font Size

Shingles Vaccine Works in Large Study

Adult Vaccine Cuts Shingles Cases by Half, Lasting Pain by 2/3

Vaccine Cuts Pain, Severity continued...

Half the people in the study got the vaccine, and half didn't. The results:

  • The vaccine cut shingles cases by 51%.
  • The vaccine reduced shingles severity by 61%.
  • The vaccine reduced cases of postherpetic neuralgia by 66.5%.

That last number is the most important one, says herpes virus expert Sam Speck, PhD, professor of microbiology and immunology at the Emory Vaccine Center and director of the center for emerging infectious diseases at Emory University in Atlanta.

"For individuals over 60, it may be worth getting vaccinated if this vaccine becomes available," Speck tells WebMD. "If the vaccine's protection was simply limited to preventing the bout of shingles, it would be less of a good idea. But it is the prevention of postherpetic neuralgia that really drives interest in this vaccine."

Merck, which makes the vaccine, already has asked the FDA to approve the vaccine. But it's not easy to make. Right now, Oxman says, his team is waiting for Merck to give them more vaccine so they can give it, as promised, to the nearly 20,000 study participants who received placebo during the study. Merck is a WebMD sponsor.

Questions Remain

Questions remain about the shingles vaccine, notes Stanford University researcher Ann Arvin, MD. Arvin's editorial accompanies the Oxman study in the NEJM.

Arvin points out that:

  • It's still not clear how long the vaccine protects against shingles and postherpetic neuralgia.
  • It's still not clear whether repeat doses of the vaccine will improve protection.
  • If a second or third dose is needed, the best vaccination schedule is not known.
  • It's still not clear whether the vaccine will work in very old people.

1 | 2

Today on WebMD

varicella zoster virus
How to recognize this painful rash.
shingles rash
Symptoms, causes, and treatment.
nurse administering flu vaccine
8 questions, answered.
senior woman
Are you more likely to get it?
shingles rash
woman holding her lower back
New PHN Drug Cuts Lingering Shingles Pain
mature man with serious expression